Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMatthew Holderfield, Mallika Singh, Elena S. Koltun et al.|Nature|2024Cited by 319
Mechanisms of resistance to active state selective tri-complex RAS inhibitorsBen Sang, Piro Lito, Alberto Vides et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 10
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMallika Singh, David Wildes, Matthew Holderfield et al.|Research Square|2023Cited by 5
Abstract A081: Resistance Mechanisms to Monotherapy RAS(ON) Multi-Selective Inhibitor Daraxonrasib (RMC-6236) in RAS Mutant PDAC Inform Therapeutic Combination StrategiesIda Aronchik, Mallika Singh, Sumit Kar et al.|Molecular Cancer Therapeutics|2025Cited by 1